睿知中国疾病研究地图
候选清单0

即将招募多发性骨髓瘤不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07376720,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 78 岁;性别:不限

    登记记录的入选字段

  2. Relapsed/refractory: no response to salvage therapy (no response is defined as not achieving minimal response [MR] or disease progression during treatment), or disease progression within 60 days after the last treatment, or disease progression after achieving MR or the above remission;

    入选标准第 10 条

    Previously received the following anti-tumor treatments (before collecting and preparing the CAR-T cells): within 14 days or at least 5 half-lives (whichever is shorter) received targeted therapy, epigenetic therapy or experimental drug treatment, or used invasive experimental medical devices; received monoclonal antibody treatment for multiple myeloma within 21 days; received cytotoxic treatment within 14 days; received proteasome inhibitor treatment within 14 days; received immunomodulatory agent treatment within 7 days; received radiotherapy within 14 days (except for fields covering ≤5% of bone marrow reserves);

    排除标准第 2 条

    Hormones: Those who are currently receiving systemic steroid therapy and whose treatment requires long-term systemic steroid therapy during the treatment period (except for inhalation or local use); and those who received systemic steroid therapy within 72 hours before the cell infusion (except for inhalation or local use);

    排除标准第 15 条

  3. The ECOG performance status score is 0-2 and the estimated survival period is more than 3 months;

    入选标准第 13 条

  4. Alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal value (ULN);

    入选标准第 15 条

    Aspartate aminotransferase (AST) ≤ 3 times ULN;

    入选标准第 16 条

    Total bilirubin ≤ 1.5 times ULN;

    入选标准第 17 条

    Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 mL/min;

    入选标准第 18 条

    Hemoglobin ≥ 50g/L (must not have received blood transfusion support within 7 days before laboratory examination);

    入选标准第 19 条

  5. Based on any of the following criteria, measurable lesions are determined during the screening: the level of single-clonal paraprotein (M-protein) in the blood ≥ 1.0 g/dL or the M-protein level in urine ≥ 200 mg/24 hours; or a light chain-type multiple myeloma diagnosed as having no measurable lesions in serum or urine: the free light chain of serum immunoglobulin ≥ 10 mg/dL and the abnormal ratio of free light chains of serum immunoglobulin κ/γ;

    入选标准第 4 条

  6. Within 3 years, diagnosed with or treated for any other aggressive malignant tumor other than multiple myeloma;

    排除标准第 1 条

    Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA titer is higher than the lower limit set by the research institution; positive for hepatitis C virus (HCV) antibody and positive for peripheral blood HCV-RNA; positive for human immunodeficiency virus (HIV) antibody; quantitative detection of cytomegalovirus (CMV) DNA is higher than the lower limit set by the research institution; positive for syphilis spirochete antibody; quantitative detection of Epstein-Barr virus (EBV) DNA is higher than the lower limit set by the research institution;

    排除标准第 5 条

  7. Pregnant or lactating women, and female subjects who plan to conceive within 2 years after the cell infusion or whose male partners plan to conceive within 2 years after the cell infusion;

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07376720,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The patient or their guardian understands and voluntarily signs the informed consent form, and is expected to complete the follow-up examinations and treatments of the research procedures;
  2. Age 18-75 years (inclusive), gender not limited;
  3. According to the IMWG diagnostic criteria, patients diagnosed with multiple myeloma;
  4. Based on any of the following criteria, measurable lesions are determined during the screening: the level of single-clonal paraprotein (M-protein) in the blood ≥ 1.0 g/dL or the M-protein level in urine ≥ 200 mg/24 hours; or a light chain-type multiple myeloma diagnosed as having no measurable lesions in serum or urine: the free light chain of serum immunoglobulin ≥ 10 mg/dL and the abnormal ratio of free light chains of serum immunoglobulin κ/γ;
  5. Has received at least three lines of treatment for multiple myeloma in the past, and should include:
  6. One proteasome inhibitor (such as bortezomib, carfilzomib, ixazomib, etc.);
  7. One immunomodulator (such as thalidomide, lenalidomide, pomalidomide, etc.);
  8. One CD38 monoclonal antibody;
  9. There is evidence that the patient's multiple myeloma disease is relapsed/refractory or primary refractory, defined as:
  10. Relapsed/refractory: no response to salvage therapy (no response is defined as not achieving minimal response [MR] or disease progression during treatment), or disease progression within 60 days after the last treatment, or disease progression after achieving MR or the above remission;
  11. Primary refractory: no MR or above treatment response has been achieved, including patients who have never achieved MR or above remission, but the M-protein has not changed significantly and there is no clinical progression evidence, and patients with primary refractory and progression, meeting the progression definition.
  12. The patient has recovered from the toxicity of previous treatment, that is, the CTCAE toxicity grade is less than 2 (unless the abnormality is related to the tumor or is judged by the investigator to be in a stable state, which has little impact on safety or efficacy);
  13. The ECOG performance status score is 0-2 and the estimated survival period is more than 3 months;
  14. Has appropriate organ function:
  15. Alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal value (ULN);
  16. Aspartate aminotransferase (AST) ≤ 3 times ULN;
  17. Total bilirubin ≤ 1.5 times ULN;
  18. Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 mL/min;
  19. Hemoglobin ≥ 50g/L (must not have received blood transfusion support within 7 days before laboratory examination);
  20. Intraocular oxygen saturation ≥ 92%;
  21. Corrected serum calcium ≤ 12.5 mg/dL (≤ 3.1 mmol/L) or free ionized calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L);
  22. Left ventricular ejection fraction (LVEF) ≥ 45%, confirmed by echocardiography that there is no pericardial effusion, and no clinically significant electrocardiogram findings;
  23. No clinically significant pleural effusion;
  24. The required venous access can be established, and there are no contraindications for white blood cell collection.

排除标准:Exclusion Criteria:

  1. Within 3 years, diagnosed with or treated for any other aggressive malignant tumor other than multiple myeloma;
  2. Previously received the following anti-tumor treatments (before collecting and preparing the CAR-T cells): within 14 days or at least 5 half-lives (whichever is shorter) received targeted therapy, epigenetic therapy or experimental drug treatment, or used invasive experimental medical devices; received monoclonal antibody treatment for multiple myeloma within 21 days; received cytotoxic treatment within 14 days; received proteasome inhibitor treatment within 14 days; received immunomodulatory agent treatment within 7 days; received radiotherapy within 14 days (except for fields covering ≤5% of bone marrow reserves);
  3. Suspected that MM has involved the central nervous system or meninges and confirmed by MRI or CT, or has other active central nervous system diseases;
  4. At the screening stage, had Waldenström macroglobulinemia, POEMS syndrome (multiple neuropathy, organ enlargement, endocrine lesion, monoclonal protein disease and skin changes) or primary AL amyloidosis;
  5. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA titer is higher than the lower limit set by the research institution; positive for hepatitis C virus (HCV) antibody and positive for peripheral blood HCV-RNA; positive for human immunodeficiency virus (HIV) antibody; quantitative detection of cytomegalovirus (CMV) DNA is higher than the lower limit set by the research institution; positive for syphilis spirochete antibody; quantitative detection of Epstein-Barr virus (EBV) DNA is higher than the lower limit set by the research institution;
  6. Those with a history of severe allergic reactions [severe allergic reactions are defined as secondary or higher-level allergic reactions, and when allergic reactions occur, any of the following clinical manifestations occur: airway obstruction (runny nose, cough, wheezing, breathing difficulty), tachycardia, hypotension, arrhythmia, gastrointestinal symptoms (nausea, vomiting), incontinence of urine and stool, laryngeal edema, bronchospasm, cyanosis, shock, cardiac and respiratory arrest) or known to be sensitive to any active ingredients of the drugs included in this test, excipients, or murine products, or cross-reactive proteins from different species;
  7. Suffering from severe heart diseases, including but not limited to severe arrhythmia, unstable angina pectoris,大面积 myocardial infarction, NYHA class III or IV cardiac insufficiency before screening, having had a myocardial infarction within ≤ 6 months before screening or having received coronary artery bypass grafting (CABG), having a history of unexplained syncope not caused by vasovagal or dehydration, severe non-ischemic cardiomyopathy history, refractory hypertension (refractory hypertension is defined as: after improving lifestyle, using reasonable and tolerable sufficient ≥ 3 types of antihypertensive drugs (including diuretics) for more than 1 month, blood pressure still cannot be controlled or taking ≥ 4 types of antihypertensive drugs can effectively control blood pressure);
  8. Systemic diseases judged by the investigator to be unstable: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
  9. Had acute/chronic graft-versus-host disease (GVHD) within 6 months before screening, or patients requiring immunosuppressive therapy for GVHD;
  10. Patients with active autoimmune or inflammatory diseases of the nervous system (such as Guillain-Barré syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically significant active cerebrovascular diseases (such as brain edema, posterior reversible encephalopathy syndrome (PRES));
  11. Those with tumor emergencies (such as spinal cord compression, intestinal obstruction, leukocyte stasis, tumor dissolution syndrome, etc.) requiring emergency treatment before screening or during reinfusion;
  12. Have infections that require antibiotic treatment, such as uncontrolled bacterial, fungal, viral or other infections;
  13. Within 1 week before blood collection for CAR-T preparation, have used drugs that affect the patient's blood count.
  14. During the screening, within 2 weeks before the planned preparation of CAR-T cells, those who are currently receiving hormones or immunosuppressive drugs, and whose preparation is judged to be affected by the study investigators:
  15. Hormones: Those who are currently receiving systemic steroid therapy and whose treatment requires long-term systemic steroid therapy during the treatment period (except for inhalation or local use); and those who received systemic steroid therapy within 72 hours before the cell infusion (except for inhalation or local use);
  16. Immunosuppressants: Those who are currently receiving immunosuppressants;
  17. Within 4 weeks before the conditioning regimen, those who have undergone major surgery (except diagnostic surgery and biopsy) or those whose major surgery is planned during the study period, or those whose surgical wounds have not fully healed before enrollment;
  18. Within 4 weeks before the screening, those who have received (attenuated) live virus vaccines;
  19. Those with severe mental disorders;
  20. Those who are heavy drinkers or have a history of drug abuse;
  21. Pregnant or lactating women, and female subjects who plan to conceive within 2 years after the cell infusion or whose male partners plan to conceive within 2 years after the cell infusion;

引自 ClinicalTrials.gov, NCT07376720, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07376720,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07376720